Exagen Inc. reported a 7% increase in revenue to $18.4 million for Q3 2026 and an 11% rise year-to-date, alongside a 12% reduction in net loss and over 30% improvement in adjusted EBITDA loss. The company’s average selling price per test grew for the 14th consecutive quarter, reflecting strong business momentum. Exagen highlighted its scientific progress at the 2026 ACR Convergence Conference and remains on track to launch a new myositis diagnostic test in early 2027, addressing an unmet clinical need. The company reaffirmed its full-year 2026 revenue guidance of $72 million to $75 million.
Exagen Inc.'s third quarter 2026 report comes as a backdrop to the health sector's activity on Pluang. For readers following US health stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: out of 150 priced stocks, 85 rose and 56 fell. Notable movers include CGC at USD 0.65 with a 1-day change of +4.37% and Pluang order activity skewed 79% Sell / 21% Buy, ABCL at USD 12.96 up 3.68% with 93% Sell / 7% Buy, and LQDA at USD 49.03 up 2.42% with 97% Sell / 3% Buy. Typical hold times range from 5 to 42 days across these names.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
